This Penny Biotech stock just doubled in a key acquisition. Should I buy shares here?
Shares of Q32 Bio (QTTB) more than doubled on December 1 after the biotech company announced a strategic agreement with Cambridge-based Akebia Therapeutics (AKBA). Q32 sold its complement phase inhibitor, ADX-097, to Akebia for $12 million in upfront payments, and the total transaction could reach $592 million across development, regulatory and commercial milestones. At its…